A pragmatic guide for management of adverse events associated with lorlatinib
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].